AIM ImmunoTech Inc. (New York Stock Exchange Arca:AIM)
| Market Cap | 7.16M-92.5% |
| Revenue (ttm) | 95.00K-21.5% |
| Net Income | -14.27M+11.7% |
| EPS | -0.36+57.7% |
| Shares Out | 39.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 532,438 |
| Open | 0.18 |
| Previous Close | 0.18 |
| Day's Range | 0.18 - 0.19 |
| 52-Week Range | 0.17 - 2.79 |
| Beta | 1.27 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 16, 2026 |
AIM ImmunoTech Inc. has a live Insider Score.
Scored on 4 qualifying trades from 1 insider in the last 90 days.
About AIM
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$AIM stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in AIM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AIM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AIM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
AIM Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New AIM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AIM from public contracts
Source: USAspending.gov
AIM Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from AIM’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score